Description: Dapatorq-V100 Tablets contains Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2 and Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.
Dosage Form: Tablets
Route of Administration: Oral
Composition: Each uncoated bilayered tablet contains:
Dapagliflozin Propanediol Monohydrate USP Eq. to Dapagliflozin 10 mg
Vildagliptin IP 100 mg (As sustained release)
Excipients q.s.
Mechanism of Action: Dapagliflozin inhibits SGLT2 thus reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin improves both fasting and post-prandial plasma glucose levels. Vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
Indications: Dapatorq-V100 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.
Dosage: As directed by the physician.
Side Effects: The following adverse reactions may occur: Genital Infections, Urinary Tract Infections, Hypoglycaemia Dizziness Rash Back Pain Dysuria Polyuria Dyslipidaemia
Contraindications: Dapatorq V100 is contraindicated in patients with known hypersensitivity to Dapagliflozin, Vildaglitin or any of the components of this product.
Drug Interactions: Diuretics, Rifampicin, Mefenamic Acid, Warfarin, Digoxin, ACE-inhibitors
Storage: Store protected from light & moisture, at a temperature not exceeding 25°C.
Presentation: 10x10 Tablets